Adagio Medical Reports Q1 Results, Highlights Strong FULCRUM-VT Trial Data & $31M Warrant Potential
ADGM sits 23% above its 52-week low of $0.74.
Summary
Adagio Medical reported Q1 2026 results with ongoing losses and low cash, but highlighted pivotal positive clinical trial data and FDA approval for its next-gen system, alongside potential for $31 million from warrant exercises.
Key Events · Earnings and Guidance · ADGM
-
Q1 2026 Financial Results
Reported nil revenue and a net loss of $7.0 million for the first quarter ended March 31, 2026, compared to a $7.7 million net loss in Q1 2025.
-
Cash Position and Warrant Potential
Cash and cash equivalents stood at $12.9 million as of March 31, 2026. The company noted potential for up to an additional $31 million in gross proceeds from the cash exercise of milestone-based warrants.
-
Pivotal FULCRUM-VT Trial Results
Announced positive late-breaking pivotal results from the FULCRUM-VT trial, demonstrating 84% freedom from implantable cardioverter defibrillator (ICD) shock at six months and a promising safety profile.
-
FDA IDE Approval for Next-Gen System
Received FDA Investigational Device Exemption (IDE) approval to expand the FULCRUM-VT trial to evaluate the next-generation vCLAS Ultra System.
Analysis · ADGM · Industrial Applications And Services
Adagio Medical reported Q1 2026 financial results, showing continued nil revenue and a net loss of $7.0 million, with cash and cash equivalents at $12.9 million. This cash position provides a short runway, especially given the prior 'going concern' warning. However, the filing also highlights significant positive clinical progress, including pivotal FULCRUM-VT trial results demonstrating 84% freedom from ICD shock and FDA IDE approval for its next-generation vCLAS Ultra System. These clinical advancements are critical for the company's path to PMA approval and commercialization, which could unlock up to $31 million in additional gross proceeds from milestone-based warrant exercises, significantly extending its financial runway.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ADGM was trading at $0.91 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $20.9M. The 52-week trading range was $0.74 to $2.58. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.